Clinical Trial

Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A Study to Investigate the Tolerability, Safety,Pharmacokinetics and efficacy of GR1603 in subjects with Systemic Lupus Erythematosus ； GR1603 injection is a monoclonal antibody targeting IFNAR1, which can block IFNAR binding to type I interferons such as IFNα and be used to treat systemic lupus erythematosus.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-22.
Status change: Recruiting → Active, Not Recruiting 2024-09-23
Trial Details
NCT Number NCT06015230
Lead Sponsor Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Conditions Lupus Erythematosus, Systemic
Enrollment 136 participants
Start Date 2022-03-08
Primary Completion 2028-06-10 (estimated)
Study Completion 2028-10-04 (estimated)
Updated on ClinicalTrials.gov 2024-09-25